A Randomized Controlled Trial of Treatment of Bacterial Vaginosis
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a double-blinded, placebo controlled, multi-center randomized trial of 482 pregnant
women who are diagnosed with Bacterial Vaginosis (BV) in the late 3rd trimester (>34 weeks).
During routine clinic visit after 34 weeks, prospective patients will be counseled about the
study. Patients who agree to be enrolled, will sign informed consent. Following enrollment,
patients will be screened for BV. Those patients who are BV positive by clinical diagnosis,
will be randomized to receive either metronidazole 500 mg BID orally for 7 days or
identically appearing placebo.